Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jan 25, 2016 in Diabetes mellitus | 0 comments

In a nutshell

This review examined the safety and effectiveness of once weekly GLP-1 receptor agonists for the treatment of type 2 diabetes. The authors concluded that once weekly  GLP-1 RA drugs are convenient, safe and effective for the treatment of type 2 diabetes.

Some background

Patients with type 2 diabetes (T2D) initially produce insulin (hormone which lowers blood sugar levels) but it fails to work in the body. Drugs such as metformin (Glucophage) aim to help insulin work in the body. However, eventually the pancreas reduces insulin production. Patients may need to be treated with a long-acting insulin such as glargine (Lantus).

Drugs such as sitagliptin (Januvia) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) increase insulin secretion. GLP-1 RA drugs may be short-acting or long-actingExenatide BID (Byetta) twice daily is a short-acting GLP-1 RA. GLP1-RA drugs which are long-acting are administered once weekly and include albiglutide (Tanzeum) and dulaglutide (Trulicity). GLP1-RA drugs are generally used in combination with other anti-diabetic agents such as metformin or insulin.

Methods & findings

This review summarized results from 33 clinical trials which investigated the safety and effectiveness of once weekly GLP-1 RA drugs. A total of 16,003 participants were included in the clinical trials. The trials compared once weekly GLP-1 RA drugs to a placebo (substance with no therapeutic effect) or to other anti-diabetic drugs.

The HbA1c (average blood glucose levels over 3 months) decreased more in participants treated with dulaglutide (-1.18%) compared to albiglutide (-0.66%). Neither albiglutide nor dulaglutide treatment promoted weight loss.

Once weekly GLP-1 RA drugs resulted in a greater reduction in HbA1c (average reduction of 0.4%) compared to sitagliptin. In comparison to daily exenatide, once weekly treatment with a GLP-1 RA resulted in a greater reduction in HbA1c (average reduction of 0.44%). In comparison to insulin glargine, once weekly treatment with GLP-1 RA resulted in a greater reduction in HbA1c (average reduction of 0.28%).

The main side effects occurring with GLP-1 RA treatment included gastrointestinal reactions and reactions at the injection site.

The bottom line

This review concluded that once weekly GLP-1 RA drugs are a convenient, safe and effective option for the treatment of T2D.


What’s next?

Consult your physician regarding the risks and benefits of GLP-1 RA drugs.

Published By :

Diabetes, Obesity and Metabolism

Date :

Nov 01, 2015

Original Title :

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

click here to get personalized updates